algorithms immunospot cellular technology limited 7 0 18 1 prism graphpad software (Cellular Technology Ltd)
Cellular Technology Ltd is a verified supplier 
Cellular Technology Ltd manufactures this product 
99
Structured Review
Cellular Technology Ltd
algorithms immunospot cellular technology limited 7 0 18 1 prism graphpad software
Algorithms Immunospot Cellular Technology Limited 7 0 18 1 Prism Graphpad Software, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 2115 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software%2C+algorithm/ImmunoSpot+Software/pm42805178-261-237-238
Average 99 stars, based on 2115 article reviews
Algorithms Immunospot Cellular Technology Limited 7 0 18 1 Prism Graphpad Software, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 2115 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software%2C+algorithm/ImmunoSpot+Software/pm42805178-261-237-238
Average 99 stars, based on 2115 article reviews
algorithms immunospot cellular technology limited 7 0 18 1 prism graphpad software - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
CTL Assay:Article Title: MSCs delivering LIGHT prime immune response against CAFs to harness antigen loss variants. Article Snippet: The tumor niche promotes immune tolerance, enabling malignant cells to evade surveillance.. Mesenchymal stem cells (MSCs) have multipotential differentiation capacity and provide a niche for bone marrow homeostasis.. MSCs home to tumor tissues, where they can differentiate into Cancer-associated fibroblasts (CAFs). Software:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Flow Cytometry:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Cytometry:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Automated:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Article Title: A Nitric Oxide–Based STING Agonist Nanoadjuvant With ICD‐Derived Membrane Antigens Unleashes Robust Antitumor Immunity Article Snippet: .. Air‐dried plates were analyzed using an automated Coagulation:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Reversed-phase High-Performance Liquid Chromatography:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. other:Article Title: PLGA-particle-based vaccine induces SARS-CoV-2-specific antibody and T-cell responses. Article Snippet: Briefly, dilutions of 2.5 105 to 1 106 freshly isolated splenocytes or lung cells, incubated for 3 days with 1000-U ml 1 IL-2 and 1-μg ml 1 R848 (Invivogen), were incubated in MultiScreenHTS PVDF Filter Plates (Merck Millipore) pre-coated with an antibody specific for IFNγ (MABTECH Cat# 3321-3-1000, RRID:AB_2123057), IgA (MABTECH Cat# 3865-3-250) or IgG (MABTECH Cat# 3825-2A) in triplicates and re-stimulated with 100-μg ml 1 full length recombinant His-tagged SARS-CoV-2-Spike S1 (RBD, Trenzyme) at 37 C in a humidified CO2 atmosphere for 24 h. Following the incubation with a biotinylated secondary antibody specific for IFNγ (MABTECH Cat# 3321-6-1000, RRID:AB_907270) or IgA IgA (1:250, MABTECH Cat# 3865-6-250) or IgG (1:250, MABTECH Cat# 3825-2A), a streptavidin–ALP enzyme conjugate (1:400, eBioscience) was added. Article Title: Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Methylcellulose Sigma-Aldrich Cat# M7027 Saponin Sigma-Aldrich Cat# 47036 4% paraformaldehyde in PBS Alfa Aesar Cat# J61899.AP SMARTscribe Reverse Transcriptase Takara Cat# 639538 1-Step Ultra TMB-ELISA Thermo Fisher Scientific Cat# 34028 Kinetics buffer FortéBio 18-1105 Critical commercial assays Universal Mycoplasma Detection Kit ATCC Cat# 30-1012K QIAGEN Multiplex PCR Kit Qiagen Cat# 206143 Plasmid Maxi Kit Qiagen Cat #12162 RNeasy Plus Mini kit Qiagen Cat# 74134 QIAamp Viral RNA extraction kit Qiagen Cat# 52904 SuperScript IV One-Step RT-PCR kit Thermo Fisher Scientific Cat# 12594025 QIAquick PCR Purification Kit Qiagen Cat# 28104 FabALACTICA Fab kit Midispin Genovis A2-AFK-100 Deposited data MeV-15 + MeV-104/MeV-F Protein DataBank PDB: 9YBY MeV-15 + MeV-104/MeV-F Electron Microscopy DataBank EMD-72759 MeV F (prefusion stabilized) Protein DataBank PDB: 8UUP Fab fragment Protein DataBank PDB: 12E8 MeV F + Fab77 Protein DataBank PDB: 8UT2 Experimental models: Cell lines Mouse-human HMMA 2.5 myeloma cell line Dr. L. Cavacini N/A VeroSLAM BEI Resources NR-55500 Vero ATCC CCL81 Human: Expi293F Thermo Fisher Scientific Cat# A14527; RRID:CVCL_D615 Hamster: ExpiCHO Thermo Fisher Scientific Cat# A29127; RRID:CVCL_5J31 Experimental models: Organisms/strains SLAMF1 IFNAR knockout mice Branka Horvat Sellin et al.27 Oligonucleotides CpG (ZOEZOEZZZZZOEEZOEZZZT oligonucleotide) Invitrogen N/A Recombinant DNA pANTS_MeV-15_mCisK_hG1 This paper N/A pANTS_MeV-16_mCisL_hG1 This paper N/A pANTS_MeV-17_mCisK_hG1 This paper N/A pANTS_MeV-22_mCisK_hG1 This paper N/A pANTS_MeV-104_mCisK_hG1 This paper N/A pANTS_MeV-15_mCisK_FAB This paper N/A pANTS_MeV-104_mCisK_FAB This paper N/A pVVC_77.4_mCisK_hG1 Zyla et al.18 N/A MeV_PreF_V3 This paper, Hashiguchi et al.12 Article Title: PLGA-particle-based vaccine induces SARS-CoV-2-specific antibody and T-cell responses. Article Snippet: Plates were washed five times with PBS and blocked at room temperature with 10% FCS supplemented IMDM (Gibco) for 2 h. 2 105 freshly isolated bone marrow derived cells were incubated in pre-coated plates in triplicates at 37 C in a humidified CO2 atmosphere for 16 h. Following the incubation with a biotinylated secondary antibody specific for IgG (1:250, MABTECH Cat# 3825-2A) and a PBS washing step, a streptavidin-FITC conjugate was added (BD bioscience). Enzyme-linked Immunospot:Article Title: A Nitric Oxide–Based STING Agonist Nanoadjuvant With ICD‐Derived Membrane Antigens Unleashes Robust Antitumor Immunity Article Snippet: .. Air‐dried plates were analyzed using an automated |